We are Sorry, This Page doesn't Exist
Translate Bio Shares Drop After Its mRNA-Based Cystic Fibrosis Candidate Did Not Improve Lung Function
Translate Bio Inc (NASDAQ: TBIO) revealed its second interim analysis from Phase 1/2 clinical trial evaluating MRT5005 in patients with cystic fibrosis (CF). Latest Ratings f.....»»
Cara Therapeutics expects interim analysis from Phase 2 trial in AD in Q2
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Metracrine achieves enrollment target for MET642 Phase 2a trial interim analysis
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase development Strong fi.....»»
Nabriva Therapeutics announces publication of analysis of LEAP 2 Phase 3 trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Can-Fite BioPharma implements interim analysis for Phase 3 Comfort trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
VBL Therapeutics announces outcome of interim analysis in OVAL Phase 3 study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
VBL Therapeutics expects interim analysis of OVAL Phase 3 study in 1Q20
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Sorrento Therapeutics presents "positive" interim results of Phase 1b RTX trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
ProQR Therapeutics expects interim data from Phase 2/2 Stellar trial in 1Q20
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
TCR2 Therapeutics expects interim update on TC-210 Phase 1/2 trial in 1H20
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
50% of Enrollment Complete for Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD Results from RECOVERY Interim Analysis Expected First Quarter 2020 Topline Data Expected Second Quarter 2020 Based on Cu.....»»
ProQR Therapeutics (PRQR) Sepofarsen Phase 1/2 Trial Topline Results - Slideshow
ProQR Therapeutics (PRQR) Sepofarsen Phase 1/2 Trial Topline Results - Slideshow.....»»
Capricor Therapeutics (CAPR) Presents Interim Results from HOPE-2 Trial for CAP-1002 - Slideshow
Capricor Therapeutics (CAPR) Presents Interim Results from HOPE-2 Trial for CAP-1002 - Slideshow.....»»
Eidos Therapeutics to present interim analysis of Phase 2 OLE study of AG10
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Bicycle Therapeutics presents data from Phase I/IIa trial evaluating BT1718
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Auris Medical expects interim analysis of TRAVERS Phase 2 trial in Q4 or 1Q20
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Abeona Therapeutics announces interim data from Phase 1/2 trial of ABO-102
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Why Capricor May Be the Next Big Name in Duchenne Muscular Dystrophy
Capricor Therapeutics shares more than doubled on Monday after the firm announced interim analysis for its Duchenne muscular dystrophy midstage trial......»»
AstraZeneca announces results from interim analysis of Phase 2 ASCEND trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»